29. Hampson AJ, Grimaldi M, Axelrod J, Wink D. 1998. Cannabidiol and (-)delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences USA 95:8268-8273.
30. Howlett AC. 1995. Pharmacology of cannabinoid receptors. Annual Review of Pharmacology and Toxicology 35:607-634.
31. IOM (Institute of Medicine). 1990. Modern Methods of Clinical Investigtion. Washington, DC: National Academy Press.
32. IOM. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: National Academy Press.
33. IOM. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: National Academy Press.
34. IOM. 1996. Pathways of Addiction: Opportunities in Drug Abuse Research. Washington, DC: National Academy Press.
35. Knoller N, Levi L, Israel Z, Razon N, Reichental E, Rappaport Z, Ehrenfreund N, Biegon A. Safety and outcome in a Phase II clinical trail of dexanabinol in severe head trauma. Congress of Neurological Surgeons Annual Meeting. Seattle, WA, Oct. 7, 1998.
36. Mechoulam R, Hanus L, Fride E. 1998. Towards cannabinoid drugs-revisited. In: Ellis GP, Luscombe DK, Oxford AW, Editors, Progress in Medicinal Chemistry. vol. 35. Amsterdam: Elsevier Science. Pp. 199-243.
37. Nainggolan L. 1997. Marijuanaa missed market opportunity? Scrip Magazine.
38. National Institutes of Health (NIH). 1999. http://www.nih.gov/grants/award/ award.htm.
39. NIDA (National Institute on Drug Abuse). 1996. Research Resources: Drug Supply Systen, 10th Edition. Rockville, MD.
40. NIH (National Institutes of Health). 1997. Workshop on the Medical Utility of Marijuana. Report to the Director, National Institutes of Health by the Ad Hoc Group of Experts. Bethesda, MD, February 19-20, 1997. Bethesda, MD: National Institutes of Health.
41. NIH. 1998. FY (1970-1997 NIH (Preliminary) competing research project applications [WWW document].URL http:/silk.nih.gov/public/cbz2rfm.@www.comic.dsncc (accessed October 1998).
42. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. 1980. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clinical Pharmacology and Therapeutics 28:409416.
43. OTA (Office of Technology Assessment). 1991. Biotechnology in a Global Economy. OTTAWA-494. Washington, DC: U.S. Government Printing Office.
44. OTA. 1993. Pharmaceutical R&D: Costs, Risks and Rewards. OTA-H-522. Washington, DC: U.S. Government Printing Office.
45. PDR (Physicians' Desk Reference). 1996. Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics Co.
46. Pertwee RG. 1997. Cannabis and cannabinoids: Pharmacology and rationale for clinical use. Pharmaceutical Science 3:539-545.
47. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. 1991. Recent clinical experience with dronabinol. Pharmacology Biochemistry and Behavior 40:695700.
48. Randall IV B. 1993. Medical Use of Marijuana: Policy and Regulatory Issues. 93-308 SPR. Washington, DC: Congressional Research Service.